Full-Time

Senior/Principal Scientist

In Vivo Bioanalytics, Gene Therapy Research

Posted on 8/1/2024

Fractyl Health

Fractyl Health

51-200 employees

Therapies for Type 2 Diabetes treatment

Biotechnology
Healthcare

Senior

Burlington, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in biology, molecular biology, physiology, or relevant research field
  • OR a Master’s degree with 10-12 years relevant industry experience
  • 5-10 years of highly relevant post-PhD experience either in an academic or industry environment
  • Experience planning and managing small and/or large animal studies
  • Experience working with preclinical and bioanalytical CROs
  • Experience in development and optimization of bioanalytical assays relevant to AAV gene therapy pharmacology and safety (e.g. biodistribution, GOI RNA expression and protein quantification, ADA, nAb/Tab, ELISpot)
  • Experience with molecular and cellular biology instruments and techniques, e.g., DNA/RNA/Protein purification, ddPCR and qPCR, flow cytometry, Western blotting, MSD, ELISAs, TapeStation, JESS
  • Experience and/or willingness to work with small and large animal models and tissues
  • Successful track record of working in high-growth and dynamic organizations
  • Demonstrated record of intellectual curiosity, innovation and creative problem solving with an entrepreneurial spirit
  • Ability to lead fast-paced projects with a keen sense of urgency to get the job done well
  • Evidence of "hands-on" experience and expertise
  • Proven and successful track record as a team-player and collaborator in small working environments
  • Highly organized and detail oriented with a passion to deliver quality results
  • Excellent verbal and written communication skills, with experience translating technical concepts into user-friendly documentation
  • Highest levels of professionalism, confidence, personal values and ethical standards
Responsibilities
  • Collaborate cross-functionally and with preclinical CROs to support the planning and execution of in vivo studies
  • Provide scientific/technical diligence and oversight on assay development activities for in vivo study sample analysis measuring gene therapy delivery, pharmacology, safety, and efficacy
  • Coordinate logistics, manage, and monitor timely completion of downstream bioanalytic analyses
  • Consolidate data across different in vivo bioanalytical workstreams toward preparation of study reports
  • Contribute to identification of potential new CRO and academic collaborative partners and assist in GLP audits
  • Develop timelines and milestones to ensure timely completion of deliverables internally and externally
  • Contribute to in vivo discovery and early proof of concept efforts for new projects in Fractyl’s pipeline
  • Prepare technical reports, summaries, protocols, quantitative analysis, and presentations for experimental results
  • Manage, train, and develop junior research scientist/s
  • Bring forward essential bioanalytic assays for assessment of immunotolerability of AAV gene therapy
  • Perform all activities in compliance with applicable regulations, Fractyl’s policies and guidelines, including, but not limited to, timely documentation of activities and maintaining all required applicable training
  • Bring a “can do” spirit to work and deliver on other responsibilities as assigned

Fractyl focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy designed to enhance the function of islet cells in the pancreas, which are essential for blood sugar regulation. By improving these cells, Fractyl aims to help patients achieve long-term remission from T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach centers on addressing the underlying mechanisms of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.

Company Stage

IPO

Total Funding

$282.2M

Headquarters

Lexington, Kentucky

Founded

2010

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for minimally invasive procedures boosts Fractyl's market potential.
  • European diabetes care market offers lucrative opportunities for Revita DMR.
  • Experienced leadership enhances Fractyl's commercial strategy and product launch readiness.

What critics are saying

  • Competition from established companies like Novo Nordisk poses a threat.
  • Regulatory challenges with FDA approval could delay Rejuva's market entry.
  • Market volatility may impact the success of Fractyl's IPO.

What makes Fractyl Health unique

  • Fractyl Health focuses on minimally invasive therapies for chronic diseases.
  • Revita DMR rejuvenates the duodenum lining, improving patient health.
  • Rejuva platform targets pancreatic islet cells for long-term T2D remission.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE